BCRX Biocryst Pharmaceuticals Earnings and EPS analysis

  1. Stocks
  2. Healthcare
  3. NASDAQ: BCRX
  4. Earnings
?
Relative Growth: Rel. Growth: 73
Relative Strength: Rel. Strength: 69
Relative Valuation: Rel. Valuation: 18
Relative Profitability: Rel. Profitability: 19

EPS in 2026 (TTM): -$1.44

Last Report Period Date: Jun 30, 2026

As of August this year, based on Biocryst Pharmaceuticals's most recent financial report, the company's trailing twelve months EPS is -$1.44. During 2025, BCRX reported a per-share earnings of $1.26, which shows a rise compared to the EPS of -$0.43 recorded in 2024. Biocryst Pharmaceuticals's EPS for the quarterly period ending on Jun 30, 2026 came in at $0.31.

BCRX earnings history

Historical annual and quarterly earnings per share (EPS) data for Biocryst Pharmaceuticals
EPS (TTM)
-$1.44
EPS Growth YoY (Quarterly)
1,450%
EPS (Quarterly)
$0.31
EPS Growth (Quarterly)
110.4%

The yearly earnings per share during 2025 was $1.26, a rise of 393% compared to -$0.43 recorded in 2024. Over the quarter ending Jun 30, 2026, the earnings per share came in at $0.31, reflecting a 1,450% increase compared to the same quarter a year earlier. As of June 2026, the TTM EPS is -$1.44. During 2024, the annual earnings per share was -$0.43, representing an increase of 63.6% compared to 2023.

BCRX EPS vs price chart

BCRX EPS growth history

Earnings per share growth rates over time
EPS Growth YoY (Quarterly)
1,450%
EPS growth YoY
393%
EPS growth 3Y avg
N/A
EPS growth 5Y avg
N/A

Biocryst Pharmaceuticals has recorded a growth in earnings per share of 1,450% over the past 12 months (YoY, quarterly).

BCRX Earnings Waterfall

Breakdown of revenue, profit and net income for Biocryst Pharmaceuticals

BCRX Earnings vs Peers

What are the earnings of BCRX compared to its peers
Stock name Price to Earnings EPS grwoth 1Y EPS grwoth 3Y EPS grwoth 5Y
RGEN Repligen Corp 241.51 289.1% -36.2% -5.3%
SRPT Sarepta Therapeutics Inc N/A -388.7% N/A N/A
NNVC Nanoviricides Inc N/A 10% N/A N/A
NVAX Novavax Inc N/A 321.1% N/A N/A
CLDX Celldex Therapeutics Inc N/A -59.2% N/A N/A
GILD Gilead Sciences Inc N/A 1,700% 23.2% 132.8%
EBS Emergent Biosolutions Inc N/A 127.2% N/A -29.9%
CVM Cel Sci Corp N/A 59% N/A N/A
BCRX Biocryst Pharmaceuticals Inc N/A 393% N/A N/A

All data is based on quarterly TTM periods, unless otherwise specified.